Transcatheter arterial chemoembolization with a finepowder formulation of cisplatin for hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 16, Issue 27, 2010, Pages 3437-3444

  Kasai, Kazuhiro ^a   Ushio, Akira ^a   Sawara, Kei ^a   Miyamoto, Yasuhiro ^a   Kasai, Yukiho ^a   Oikawa, Kanta ^a   Kuroda, Hidekatsu ^a   Takikawa, Yasuhiro ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; DDPH; Doxorubicin; Hepatocellular carcinoma; Transcatheter arterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DECARBOXYPROTHROMBIN; DOXORUBICIN; GELATIN SPONGE; GELPART; IODINATED POPPYSEED OIL; IOMEPROL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DOSAGE FORM; POWDER;

ABDOMINAL PAIN; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER FATIGUE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; ECHOGRAPHY; FEMALE; FEVER; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER ABSCESS; LIVER ANGIOGRAPHY; LIVER ARTERIOGRAPHY; LIVER CELL CARCINOMA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHLEBOGRAPHY; PREDICTOR VARIABLE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SIDE EFFECT; SUPERIOR MESENTERIC ARTERY; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM; LIVER NEOPLASMS; MEDICINAL CHEMISTRY; MIDDLE AGED; POWDER; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMISTRY, PHARMACEUTICAL; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DISEASE-FREE SURVIVAL; DOSAGE FORMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POWDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954857745     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i27.3437     Document Type: Article

References (37)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
3. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472
4. La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000; 36: 909-915
5. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-4972
6. Ohtomo K, Furui S, Kokubo T, Yamauchi T, Itai Y, Yashiro N, Iio M. Transcatheter arterial embolization (TAE) in treatment for hepatoma--analysis of three-year survivors. Radiat Med 1985; 3: 176-180
7. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62 Suppl 1: 64-68
8. Shiina S, Tagawa K, Unuma T, Terano A. Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol 1990; 154: 947-951
9. Kanematsu T, Furuta T, Takenaka K, Matsumata T, Yoshida Y, Nishizaki T, Hasuo K, Sugimachi K. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989; 10: 98-102
10. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148: 397-401
11. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
12. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
13. Shimamura Y, Gunvèn P, Takenaka Y, Shimizu H, Shima Y, Akimoto H, Arima K, Takahashi A, Kitaya T, Matsuyama T. Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE). Cancer 1988; 61: 238-242
14. Takayasu K, Suzuki M, Uesaka K, Muramatsu Y, Moriyama N, Yoshida T, Yoshino M, Okazaki N, Hasegawa H. Hepatic artery embolization for inoperable hepatocellular carcinoma; prognosis and risk factors. Cancer Chemother Pharmacol 1989; 23 Suppl: S123-S125
15. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 163: 345-351
16. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992; 31 Suppl: S1-S6
17. Uchiyama N, Kobayashi H, Nakajo M, Shinohara S. Treatment of lung cancer with bronchial artery infusion of cisplatin and intravenous sodium thiosulfate rescue. Acta Oncol 1988; 27: 57-61
18. Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, Araki Y, Nishimura Y. Long-term results of lipiodoltranscatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 2000; 23: 564-568
19. Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T, Kajiyama G. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001; 12: 847-854
20. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85
21. Hermanek P, Scheibe O, Spiessl B, Wagner G. [TNM classification of malignant tumors: the new 1987 edition] Rontgenblatter1987; 40: 200
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mc-Fadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655
23. Nakakuma K, Tashiro S, Hiraoka T, Uemura K, Konno T, Miyauchi Y, Yokoyama I. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983; 52: 2193-2200
24. Jinno K, Moriwaki S, Tanada M, Wada T, Mandai K, Okada Y. Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992; 31 Suppl: S7-S12
25. Imaeda T, Yamawaki Y, Seki M, Goto H, Iinuma G, Kanematsu M, Mochizuki R, Doi H, Saji S, Shimokawa K. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol 1993; 16: 209-213
26. Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Iwata R, Furukawa H, Moriyama N, Sakamoto M, Hirohashi S. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology 2000; 58: 293-299
27. Takahashi K, Ebihara K, Honda Y, Nishikawa K, Kita M, Oomura M, Shibasaki C. [Antitumor activity of cis-dichlorodiammineplatinum(II) and its effect on cell cycle progression] Gan To Kagaku Ryoho 1982; 9: 624-631
28. Morimoto K, Sakaguchi H, Tanaka T, Yamamoto K, Anai H, Hayashi T, Satake M, Kichikawa K. Transarterial chemoembolization using cisplatin powder in a rabbit model of liver cancer. Cardiovasc Intervent Radiol 2008; 31: 981-985
29. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S, Fujita M, Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989; 97: 965-971
30. Yamamoto K, Shimizu T, Narabayashi I. Intraarterial infusion chemotherapy with lipiodol-CDDP suspension for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2000; 23: 26-39
31. Doroshow JH, Locker GY, Myers CE. Experimental animal models of adriamycin cardiotoxicity. Cancer Treat Rep 1979; 63: 855-860
32. Olson HM, Capen CC. Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations. Lab Invest 1977; 37: 386-394
33. Itsubo M, Ishikawa T, Toda G, Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 1994; 73: 298-303
34. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 129-134
35. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469
36. Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, Kim WT. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol 2008; 9: 534-540
37. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000; 88: 1574-1581